Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review). - Orditura,M..; Quaglia,F..; Morgillo,F..; Martinelli,E..; Lieto,E..; De Rosa,G..; et,al.. (Oncol Rep, 2004)